News | April 12, 2025
Morepen to add 1,000 medical representatives
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Subscribe To Our Newsletter & Stay Updated
